How could venetoclax combinations improve outcome in high-risk MDS?

During the EHA 2022 Congress, the MDS Hub was pleased to speak with Jacqueline Garcia, Dana-Farber Cancer Institute, Boston, US. We asked, How could venetoclax combinations improve outcome in high-risk MDS?

Garcia begins by discussing current ongoing trials investigating venetoclax combinations, including the phase III VERONA study. Garcia goes on to talk about the use of venetoclax with HMA therapy for patients with relapsed/refractory disease, and the response and remission rates of different combinations.